Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · Real-Time Price · USD
4.010
-0.270 (-6.31%)
At close: Nov 4, 2024, 4:00 PM
4.100
+0.090 (2.24%)
Pre-market: Nov 5, 2024, 8:10 AM EST
Mereo BioPharma Group Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2015 |
| Revenue | 1 | 10 | - | 36.46 | - | - | Upgrade
|
| Cost of Revenue | -0.51 | 2.57 | -1.15 | 17.91 | - | - | Upgrade
|
| Gross Profit | 1.51 | 7.43 | 1.15 | 18.56 | - | - | Upgrade
|
| Selling, General & Admin | 23.08 | 18.42 | 26.11 | 15.93 | 21.22 | 15.56 | Upgrade
|
| Research & Development | 16.33 | 16.14 | 27.74 | 23.56 | 16.35 | 23.61 | Upgrade
|
| Operating Expenses | 39.41 | 34.56 | 53.84 | 39.49 | 37.57 | 39.16 | Upgrade
|
| Operating Income | -37.9 | -27.14 | -52.7 | -20.94 | -37.57 | -39.16 | Upgrade
|
| Interest Expense | -1.69 | -2.88 | -4.18 | -3.78 | -6.23 | -4.6 | Upgrade
|
| Interest & Investment Income | 2.63 | 2.13 | 0.84 | 0 | 0.01 | 0.18 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.31 | -2.35 | 2.72 | -0.95 | -1.82 | 0.48 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.72 | 0.24 | 10.37 | 39.79 | -110.01 | 0.64 | Upgrade
|
| EBT Excluding Unusual Items | -37.38 | -30 | -42.94 | 14.13 | -155.62 | -42.45 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | 0.04 | 0.19 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 0.11 | -10.87 | - | Upgrade
|
| Other Unusual Items | - | - | - | - | - | 1.14 | Upgrade
|
| Pretax Income | -37.38 | -30 | -42.94 | 14.24 | -166.45 | -41.12 | Upgrade
|
| Income Tax Expense | -0.53 | -0.53 | -0.72 | 1.52 | -2.82 | -6.27 | Upgrade
|
| Net Income | -36.85 | -29.47 | -42.22 | 12.73 | -163.63 | -34.84 | Upgrade
|
| Net Income to Common | -36.85 | -29.47 | -42.22 | 12.73 | -163.63 | -34.84 | Upgrade
|
| Shares Outstanding (Basic) | 140 | 132 | 121 | 106 | 68 | 18 | Upgrade
|
| Shares Outstanding (Diluted) | 140 | 132 | 121 | 111 | 68 | 18 | Upgrade
|
| Shares Change (YoY) | 12.05% | 9.33% | 8.63% | 63.82% | 279.04% | 25.69% | Upgrade
|
| EPS (Basic) | -0.26 | -0.22 | -0.35 | 0.12 | -2.41 | -1.95 | Upgrade
|
| EPS (Diluted) | -0.26 | -0.22 | -0.35 | -0.23 | -2.41 | -1.95 | Upgrade
|
| Free Cash Flow | -20.03 | -21.13 | -48.83 | -5.77 | -28.36 | -45.95 | Upgrade
|
| Free Cash Flow Per Share | -0.14 | -0.16 | -0.40 | -0.05 | -0.42 | -2.57 | Upgrade
|
| Gross Margin | 150.90% | 74.26% | - | 50.89% | - | - | Upgrade
|
| Operating Margin | -3790.40% | -271.36% | - | -57.42% | - | - | Upgrade
|
| Profit Margin | -3684.70% | -294.66% | - | 34.90% | - | - | Upgrade
|
| Free Cash Flow Margin | -2002.50% | -211.32% | - | -15.83% | - | - | Upgrade
|
| EBITDA | -37.31 | -26.57 | -52.52 | -20.86 | -35.97 | -37.59 | Upgrade
|
| EBITDA Margin | - | -265.70% | - | -57.22% | - | - | Upgrade
|
| D&A For EBITDA | 0.59 | 0.57 | 0.18 | 0.07 | 1.6 | 1.58 | Upgrade
|
| EBIT | -37.9 | -27.14 | -52.7 | -20.94 | -37.57 | -39.16 | Upgrade
|
| EBIT Margin | - | -271.36% | - | -57.42% | - | - | Upgrade
|
| Effective Tax Rate | - | - | - | 10.65% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.